Market Research Industry Reports

Ra Pharmaceuticals Inc (RARX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Ra Pharmaceuticals Inc (Ra Pharmaceuticals) is a clinical stage biopharmaceutical company that develops therapeutics for the treatment of diseases caused due to uncontrolled activation of the complement system. The company discovers and develops peptides and small molecules that target key components of the complement cascade. Its lead product candidate, RA101495 is a self-administered subcutaneous (SC) injection into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Ra Pharmaceuticals pipeline also includes RA101495, an administered SC, to treat debilitating complement-mediated diseases such as refractory generalized myasthenia gravis (rMG), and lupus nephritis (LN). The companys pipeline products are based on its proprietary peptide chemistry platform. Ra Pharmaceuticals is headquartered on Cambridge, Massachusetts, the US.

Ra Pharmaceuticals Inc (RARX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.




Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Ra Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Ra Pharma Raises USD58.5 Million in Series B Financing 11
Ra Pharma Raises US$8.6 Million In Second Tranche Of Series A Financing 13
Licensing Agreements 14
Merck Enters into Licensing Agreement with Ra Pharma 14
Equity Offering 16
Ra Pharma Prices Public Offering of Shares for USD50.4 Million 16
Ra Pharma Prices IPO for USD91 Million 18
Ra Pharmaceuticals Inc - Key Competitors 20
Ra Pharmaceuticals Inc - Key Employees 21
Ra Pharmaceuticals Inc - Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Financial Announcements 23
Mar 14, 2018: Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 23
Nov 09, 2017: Ra Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update 25
Aug 09, 2017: Ra Pharmaceuticals Reports Second Quarter 2017 Financial Results 26
May 11, 2017: Ra Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update 28
Mar 06, 2017: Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 29
Corporate Communications 31
Apr 18, 2018: Ra Pharmaceuticals Names John C. King as Chief Commercial Officer 31
Government and Public Interest 32
Jul 18, 2017: OMRF researcher tests new approach for treating deadly blood infection 32
Clinical Trials 33
Apr 26, 2017: Ra Pharmaceuticals Initiates Dosing of RA101495 in PNH Patients 33
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34

List Of Tables

List of Tables
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ra Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Ra Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Ra Pharma Raises USD58.5 Million in Series B Financing 11
Ra Pharma Raises US$8.6 Million In Second Tranche Of Series A Financing 13
Merck Enters into Licensing Agreement with Ra Pharma 14
Ra Pharma Prices Public Offering of Shares for USD50.4 Million 16
Ra Pharma Prices IPO for USD91 Million 18
Ra Pharmaceuticals Inc, Key Competitors 20
Ra Pharmaceuticals Inc, Key Employees 21

List Of Figures

List of Figures
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Ra Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9

Abbott Laboratories (ABT) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Abbott Laboratories (Abbott) develops, manufactures, and sells a diversified range of healthcare products including drugs, diagnostics, branded generics, and vascular and nutritional products. The companys products comprise specialized medicines; medical

USD 250View Report

Ra Pharmaceuticals Inc (RARX) - Medical Equipment - Deals and Alliances Profile

Ra Pharmaceuticals Inc (Ra Pharmaceuticals) is a clinical stage biopharmaceutical company that develops therapeutics for the treatment of diseases caused due to uncontrolled activation of the complement system. Ra Pharmaceuticals

USD 250View Report

Alexza Pharmaceuticals Inc - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Alexza Pharmaceuticals Inc (Alexza), a wholly owned subsidiary of Ferrer Therapeutics Inc, focuses on the research, development and commercialization of novel, proprietary products for the treatment of acute central nervous

USD 250View Report

Ra Pharmaceuticals Inc (RARX) - Medical Equipment - Deals and Alliances Profile

Ra Pharmaceuticals Inc (Ra Pharmaceuticals) is a clinical stage biopharmaceutical company that develops therapeutics for the treatment of diseases caused due to uncontrolled activation of the complement system. Ra Pharmaceuticals

USD 250View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Apr 2018
No. of Pages :34
Country :United States of America
Category :Pharmaceuticals and Healthcare
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube